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We have previously shown that hu-
man endogenous retrovirus-W-
encoded fusogenic membrane pro-
tein syncytin-1 plays a role in the
pathogenesis of mycosis fungoides
(MF), the most common primary
cutaneous T-cell lymphoma (CTCL)
(Maliniemi et al., 2013). The expression
of syncytin-1 protein was detected in 15
of 30 MF skin lesions but not in skin-
homing nonmalignant lymphocytes.
Primary cutaneous CD30-positive lym-
phoproliferative disorders, including
lymphomatoid papulosis and primary
cutaneous anaplastic large cell lym-
phoma, are the second most common
form of CTCLs and represent approxi-
mately 25% of all CTCLs (Nikolaenko
et al., 2019; Willemze et al., 2019).This study examined the expression and
functional properties of syncytin-1 in
verified cell lines of the aforementioned
forms of CTCLs and also its presence in
the extracellular vesicles (EVs) released
by the malignant cells.
Human endogenous retrovirus-
driven syncytin-1 expression is upre-
gulated in a wide variety of human
malignancies, such as rectal and colo-
rectal cancer, prostate cancer, bladder
cancer, leukemia, and lymphoma
(Bastida-Ruiz et al., 2016). Function-
ally, upregulated syncytin-1 has been
shown to promote the cell-to-cell
fusion of endometrial carcinoma cells
(Strick et al., 2007) and breast cancer or
squamous cell carcinoma cells to
endothelial cells (Bjerregaard et al.,
2006). Despite these observations, therole of syncytin-1 in cancer remains
poorly understood.
EVs contain a variety of proteins,
lipids, RNAs, and DNA and have
recently emerged as an important form
of intercellular communication in can-
cer (Ya´n˜ez-Mo´ et al., 2015). Malignant
cell-derived EVs can be released into
the circulation and transfer their con-
tents to nontumor cells to reprogram
target cell function or to prepare met-
astatic niches (Maas et al., 2017). The
current knowledge on the molecular
mechanisms of the fusogenic properties
of EVs are not yet fully characterized,
but syncytins are anticipated to be
involved in the binding of EVs to target
cells, a process preceding fusion (Prada
and Meldolesi, 2016).
Using immunocytochemistry and
western blot analyses (Supplementary
Materials), we observed that both
the syncytin-1 protein (Figure 1) and
its receptors ASCT1 and ASCT2
(Supplementary Figure S1) are
expressed in CTCL cell lines represent-
ing MF (MyLa cell line), lymphomatoid
Figure 1. Syncytin-1 and CD30 are expressed in CTCL cell lines. (a) The left-hand panel shows high
expression of syncytin-1 (turquoise) in the CTCL and BeWo cell lines as detected by
immunocytochemistry. Normal T cells as reference. The right-hand panel shows CD30 (dark brown)
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anaplastic large cell lymphoma (Mac-
2A), and also in the BeWo cell line,
which is known to express syncytin-1
(Cheynet et al., 2005). Normal T cells
showed only very limited syncytin-1
expression (Figure 1a) (Sun et al.,
2016). To analyze the presence of
syncytin-1 as cargo of EVs, we isolated
EVs from the cell culture medium of
the aforementioned cell lines using
ultracentrifugation. Upon isolation,
nanoparticle tracking analysis was
employed to determine the amount and
size distribution of cell-derived EVs
(Supplementary Figure S2). The content
of the EVs was subsequently analyzed
by western blotting with syncytin-1-
specific antibody and antibodies
against HSP70, RAB5, and TSG101 to
confirm the specificity of EVs
(Figure 2a). Syncytin-1 protein was
detected on the surface of EVs as
confirmed by immunoelectron micro-
scopy (Figure 2b).
The full-length transmembrane 73
kDa syncytin-1 protein (composed of
surface and transmembrane subunits)
was most prominent in the three CTCL
cell lines and in the reference BeWo
cell line, whereas an additional 63
kDa form was detected in the CTCL
cell lines only (Figure 1b). This 63 kDa
variant could represent a partially
glycosylated protein or a cell type-
specific splicing variant, since the
expression of endogenous retroviral
glycoproteins is known to be
controlled by tissue-specific pre-
mRNA splicing (Trejbalova´ et al.,
2011). Moreover, EVs derived from
the CTCL and BeWo cell lines=
expression in the Mac-1, Mac-2A, and MyLa cell
lines but not in BeWo cells. Bar ¼ 20 mm. (b)
Western blot analysis of CTCL and BeWo cell
lines confirms the most abundant syncytin-1
expression in Mac-2A cell line. The densitometric
values of syncytin-1 gp73 normalized against
b-actin were 1 (Mac-1), 1.71 (Mac-2A), 1 (MyLa),
and 0.98 (BeWo). The corresponding values for
syncytin-1 gp63 were 0.61, 1.83, 0.56, and 0,
respectively. The right-hand panel shows syncytin-
1 expression silencing in BeWo cells using Dox to
induce shSyn. BeWo, chorion carcinoma; CTCL,
cutaneous T-cell lymphoma; Dox, doxycycline;
Mac-1, lymphomatoid papulosis; Mac-2A,
primary cutaneous anaplastic large cell
lymphoma; MyLa, mycosis fungoides; pTIP,
control plasmid; shSyn, short hairpin RNA
knockdown.
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Figure 2. Syncytin-1 is detected on EVs derived from CTCL cell lines and BeWo cells. (a) EV-derived syncytin-1 is most prominently detected in the Mac-2A and
BeWo cell lines by western blot analysis. The molecular weight of EV-derived syncytin-1 is 63 kDa, while the BeWo cell line lysate includes the full-length gp73
form. HSP70, RAB5, and TSG101 identify EVs. (b) Immunoelectron microscopy confirms syncytin-1 on EVs by 5 nm colloidal gold particles. The 15 nm gold
particles (red arrowheads) depict the CD63 marker of EVs. The BeWo-derived EVs are typified as 50 nm vesicles with a phospholipid layer and electron-dense
inner layer (black arrow). The bottom panel shows CD30 in CTCL cell line-derived EVs (15 nm gold particles, red arrowheads). The negative controls are
immunostained without primary antibodies. Bar ¼ 500 nm. BeWo, chorion carcinoma; CTCL, cutaneous T-cell lymphoma; EV, extracellular vesicle; Mac-1,
lymphomatoid papulosis; Mac-2A, primary cutaneous anaplastic large cell lymphoma; MyLa, mycosis fungoides.
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form. Several studies have reported
changes in the glycosylation patterns
of EVs in pathological conditions
(Ya´n˜ez-Mo´ et al., 2015). Further
studies are needed to investigate if this
size variation of syncytin-1 plays a
specific role in the pathomechanism of
CTCL. In addition, we observed the
most abundant syncytin-1 expression
in Mac-2As and their EVs. This
possibly reflects an advanced disease
stage, since Mac-2A was established
from the same patient as Mac-1 after
progression to an aggressive primary
cutaneous anaplastic large cell lym-
phoma. A knockdown study of
syncytin-1 in the BeWo cell line veri-
fied the specificity of syncytin-1Journal of Investigative Dermatology (2020), Volumantibody used for immunoblotting
(Figure 1b, right panel).
In preliminary assays to assess the
fusogenic effect of syncytin-1 on T
cells, we transiently transfected
HEK293T cells with phCMV plasmids
encoding either human nonfusogenic
(gp60) or fusogenic (env) syncytin-1
proteins. We hypothesized that upon
expression in cells, these proteins
would be captured in EVs released from
the cells. Supernatants collected and
cleared of transfected HEK293T cells
were then applied onto the Jurkat T-cell
leukemia cells, and the cell size was
analyzed by flow cytometry 24 hours
later. We observed an almost two-fold
increase in the amount of large cells
upon treatment with the supernatante 140harvested from fusogenic env-
transfected cells compared with the
nonfusogenic gp60 (Supplementary
Figure S3a). Jurkat cells grown 48
hours in the supernatant from env-
transfected cells formed plasma
membrane-enveloped giant cells,
which were undetectable in the control
gp60-treated cells (Supplementary
Figure S3b).
In addition to syncytin-1, we also
studied the eventual release of the
tumor-associated antigen CD30
(Figure 1a) in EVs. CD30 has been
detected in EVs released by Hodgkin’s
lymphoma cells. CD30 communicates
with bystander cells to allow the indi-
rect binding of brentuximab vedotin, a
monoclonal antieCD30 antibody-drug
SUPPLEMENTARY MATERIAL
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ment of MF (Hansen et al., 2016;
Whittaker et al., 2016). Using immu-
noelectron microscopy, we detected
and confirmed CD30 expression in the
CTCL cell line-released EVs
(Figure 2b). Thus, our observations are
analogous to those in Hodgkin’s lym-
phoma and may be relevant for the
favorable clinical responses even in
immunohistologically CD30-negative
MF cases (Welborn and Duvic, 2019).
Taken together, the presence of
syncytin-1, a fusogen, and its receptors
in several CTCL cell lines, refers to its
potential role in cancer cell fusion
mechanisms, similar to the one used
by placental trophoblasts (Bastida-Ruiz
et al., 2016). We show that tumor cell-
secreted EVs carry syncytin-1 protein,
which may be transferred to recipient
cells by the EVs to mediate membrane
fusion and transfer tumor cell signals.
Thus, we propose that studies on the
content and biological function of EVs
in CTCL patients will be of pivotal
importance in developing novel ther-
apeutic regimens for the currently
incurable CTCL pathologies.
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SUPPLEMENTARY MATERIAL AND
METHODS
Cell lines
We used CTCL cell lines representing
MF (MyLa cell line), lymphomatoid
papulosis (Mac-1), and primary cuta-
neous anaplastic large cell lymphoma
(Mac-2A) (Netchiporouk et al., 2017).
The Mac-1 cell line is derived from
circulating Se´zary-like cells in the pe-
ripheral blood of a patient with indo-
lent lymphomatoid papulosis, while
Mac-2A was established from skin tu-
mor nodules of the same patient after
progression to aggressive primary
cutaneous anaplastic large cell lym-
phoma (Davis et al., 1992). Although
clonally related, Mac-1 and Mac-2A
are genomically and transcriptionally
distinct (Ehrentraut et al., 2013).
The MF-derived cell line MyLa and
human embryonic kidney cell line
HEK293T were grown in DMEM sup-
plemented with Glutamax, penicillin-
streptomycin, and 10% fetal bovine
serum (FBS) (Gibco, Thermo Fisher
Scientific, Waltham, MA). The Mac-1
and Mac-2A cell lines were grown in
RPMI 1640 medium supplemented
with Glutamax, penicillin-
streptomycin, and 10% FBS. The hu-
man BeWo chorioncarcinoma cell line
was maintained in Ham’s F12 medium
supplemented with Glutamax,
penicillin-streptomycin, and 10% FBS.
Normal T cells were isolated from a
buffy coat of a healthy blood donor
(Finnish Red Cross Blood Service, Hel-
sinki, Finland) with the Lympholyte-H
gradient separation method (CL5015,
Cedarlane Corporation, Burlington,
ON, Canada) followed by enrichment
with a Pan T cell Isolation Kit (130-096-
535, Milteney Biotec, Auburn, CA)
according to the manufacturer’s in-
structions. The enriched cells were
immunostained with CD3 and CD19
antibodies and analyzed by flow
cytometry (Biomedicum Flow Cytom-
etry Core, Helsinki, Finland) and
immunocytochemistry staining with
CD3 antibody (MF7254, Dako,
Glostrup, Denmark) to confirm the T
cell nature of the enriched cells (data
not shown). The cell lines were
authenticated at the Finnish Institute for
Molecular Medicine, Helsinki, Finland,
and tested routinely for mycobacterial
contamination using a MycoAlert
Mycoplasma Detection Kit (LT07,
Lonza, Basel, Switzerland).
Immunocytochemistry
Immunocytochemistry was used to the
detect expression of syncytin-1 (1:25,
SC-50369, Santa Cruz Biotechnology,
Santa Cruz, CA), ASCT-1 (1:25 or 1:5,
SC-134846, Santa Cruz Biotech-
nology), and ASCT-2 (1:25, 5100, Cell
Signaling Technology, Leiden,
Netherlands) in cytocentrifuge prepa-
rations of Mac-1, Mac-2A, Myla,
BeWo, and T cells. AntieCD30 anti-
body (1:400, 134080, Abcam, Cam-
bridge, UK) was used to detect CD30
expression on CTCL and BeWo cells.
The ImmPRESS Reagent kit (MP-7500,
Vector Laboratories, Burlingame, CA)
was used according to the manufac-
turer’s instructions. NovaRed (SK-4800,
Vector Laboratories) and Mayer’s
hemalum solution (Merck, Darmstadt,
Germany) were used as chromogens for
ASCT-1/ASCT-2 receptors and CD30.
Horseradish Peroxidase Green substrate
buffer (KDB-10049, Nordic BioSite,
Ta¨by, Sweden) and Nuclear Fast red
(60700 Sigma-Aldrich, Darmstadt,
Germany) were used for syncytin-1.
EV purification and analyses
Ultracentrifugation was used to isolate
the EVs. Cell lines were grown for 72
hours in supplemented media as
described above, but 10% EV-depleted
FBS was used. FBS was depleted from
EV using polyethylene glycol (PEG).
Heat-inactivated FBS (Gibco, Thermo
Fisher Scientific) was treated with PEG
(P6667, Sigma-Aldrich, St. Louis, MO).
A sterile-filtered (0.2 mm filter) 50% (w/
v) stock solution of PEG prepared in 1
Dulbecco’s phosphate buffered saline
(PBS) was protected from light and
stored at 4 C. The FBS and PEG stock
solutions were mixed in a 5:1 ratio by
gently inverting 5 to 10 times and
incubated for 2 hours at 4 C protected
from light before centrifugation for 30
minutes at 4 C at 1,500g in a swinging-
bucket rotor. The supernatant was
collected leaving a layer of at least 0.5
cm on top of the pellet, and sterile
filtered (0.1 mm filter) into aliquots
stored at e20 C until use. For EV pu-
rification, cell supernatants were
centrifuged at 3,000g at 4 C for 25
minutes, followed by centrifugation at
100,000g at 4 C for 2 hours to isolate
the microvesicle and exosome frac-
tions. EV pellets were washed with 0.1
mm filtered Dulbecco’s PBS, followed
by centrifugation at 100,000g at 4 C
for 2 hours. Purified EV samples were
analyzed by nanoparticle tracking
analysis using Nanosight model LM14
(Malvern Panalytical Ltd, Malvern,
United Kingdom) equipped with blue
(404 nm, 70 mW) laser and a Scientific
Complementary metal-oxide-semi-
conductor camera. The samples were
diluted in Dulbecco’s PBS, and three
60-second videos were recorded using
camera level 13. The data were
analyzed using Nanoparticle Tracking
Analysis software 3.0 (Malvern Pan-
alytical Ltd).
Western blot analyses of cell lines
and EVs
Mac-1, Mac-2A, MyLa, and BeWo cells
were harvested either by centrifugation
or mechanical scraping and washed
twice with ice-cold PBS. Cell pellets
were resuspended in 1 PBS buffer/
0.5% Triton X-100 with EDTA-free
protease inhibitors (Roche, Basel,
Switzerland) and incubated on ice for
60 minutes. The protein concentration
was determined using the DC protein
assay kit (Bio-Rad, Go¨teborg, Sweden).
A total of 30 mg and 40 mg of protein
was used for ASCT-1/ASCT-2 and
syncytin-1 western blot analyses,
respectively. The samples were boiled
at 95 C for 5 minutes in Laemmli
Sample Buffer (Bio-Rad) with 2-
mercaptoethanol. Protein lysates were
separated by 10% SDS-PAGE electro-
phoresis and transferred onto a nitro-
cellulose membrane (Whatman,
Boston, MA) at 100 V for 90 minutes.
Membranes were incubated with
antieASCT-1 (1:200, SC-134846, Santa
Cruz Biotechnology), antieASCT-2
(1:200, 5100, Cell Signaling Technol-
ogy), and antiesyncytin-1 (1:200,
SC-50369, Santa Cruz Biotechnology)
antibodies overnight at 4 C. Incuba-
tion with antieb-actin antibodies
(4970L, 1:1,000, Cell Signaling Tech-
nology) served as a loading control.
After washing, the membranes were
incubated with antierabbit horseradish
peroxidase-conjugated secondary anti-
body (PO448, Dako) for 1 hour at room
temperature. The proteins were detec-
ted using Clarity ECL reagent (Bio-Rad),
and expression values were normalized
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against b-actin using the ChemiDoc MP
Imaging System (Bio-Rad). Adjusted
density values were calculated using
Image Lab software (Bio-Rad). Western
blot analyses of EVs were performed
using 5 mg of protein. The samples were
boiled at 95 C for 5 minutes in
Laemmli Sample Buffer (Bio-Rad) with
2-mercaptoethanol and additional SDS
(total 8%). Protein lysates were sepa-
rated as described above. In addition to
probing with antiesyncytin-1 antibody,
antieHSP70 (1:500, 610608, BD Bio-
sciences, San Jose, CA), antieRAB5
(1:100, PA5-29022, ThermoFisher Sci-
entific), and antieTSG101 (1:100,
MA1-23296, ThermoFisher Scientific)
antibodies were used as EV-specific
markers, followed by incubation with
antierabbit or antiemouse horseradish
peroxidase-conjugated secondary anti-
body (PO448 or PO447, Dako).
Knockdown assay of syncytin-1
BeWo cells were transduced with pTIP
and pTIP-short hairpin RNA knock-
down lentiviruses and selected using 3
mg/ml puromycin (Sigma-Aldrich, St.
Louis, MO) to stably express either
control plasmid (pTIP) or a TetON-
inducible short hairpin RNA knock-
down construct against syncytin-1
(pTIP-short hairpin RNA knockdown).
The vectors were kindly provided by Dr
Marcus Peter, Northwestern University,
Chicago, IL, and published by Hau et.
al. (2012). The sequence of the knock-
down oligo was already published by
Aagaard et al. (2012). The expression of
Syncytin-1 short hairpin RNA was
induced using 100 ng/ml doxycycline
(Sigma-Aldrich, St. Louis, MO) for 10
days. Cells were then lysed and
probed for syncytin-1 using Santa Cruz
antiesyncytin-1 antibody (SC-50369,
Santa Cruz Biotechnology).
Immunoelectron microscopy
EV samples from cell lines were pre-
pared for electron microscopy and
imaged as previously described (Puhka
et al., 2017) with the addition of an
immunostaining step. Briefly, after be-
ing loaded onto 200 mesh copper grids,
the samples were permeabilized with
0.01% saponin with a prefixation of 2%
paraformaldehyde. The samples were
then incubated with or without (nega-
tive control) antiesyncytin-1 antibody
(1:100, SC-50369, Santa Cruz Biotech-
nology) and antieCD30 antibody
(1:400, 134080, Abcam) followed by 5
nm or 15 nm colloidal gold conjugated
goat-antierabbit-IgG (1:150, BBI Solu-
tions, Cardiff, UK), respectively. Next, a
post-fixation step with 1% glutaralde-
hyde was performed. In addition,
antieCD63 staining was performed as
an EV-specific control. The samples
were blocked and incubated with
antieCD63 antibody (1:250, Pel-
icluster, Sanquin, Amsterdam, The
Netherlands) followed by 10-nm
colloidal gold conjugated goat-antie
mouse-IgG secondary antibody (1:80,
BBI Solutions). All the samples were
viewed with transmission electron mi-
croscopy using Jeol JEM-1400 (Jeol Ltd,
Tokyo, Japan). Images were taken with
a Gatan Orius SC 1000B CCD-camera
(Gatan Inc, Pleasanton, CA).
Cell fusion assay of syncytin-1
Human embryonic kidney HEK293T
cells were seeded a day before trans-
fection. On the day of transfection,
DMEM-containing EV-depleted FBS
(centrifuged at 100,000g for 18 hours)
was placed onto cells, and the cells
were transfected with 1.5 mg of plas-
mids according to manufacturer’s in-
structions using Lipofectamine 2000
(Thermo LifeSciences, Carlsbad, CA).
The nonfusogenic recombinant form of
pcDNAeCMV-human gp60 syncytin-1
(hydrophobic tail deleted and RNKR
cleavage site mutated) (Antony et al.,
2007) and fusogenic pcDNAeCMV-
human env syncytin-1 plasmids were
used (a kind gift from Dr. Francois
Mallet, BioMerieux, France). Approxi-
mately 6 hours after the addition of
lipofectamine complexes, media were
replaced and supplemented with EV-
depleted FBS. The following day,
media from each transfection were
harvested, and cells and debris were
removed by centrifugation (860g for 5
minutes). Jurkat cells were counted,
and 80,000 to 200,000 cells were
resuspended into media harvested
from the transfected HEK293T cells.
Approximately 24 hours later, the Jurkat
cells were harvested, fixed for 30 mi-
nutes at room temperature with 2%
paraformaldehyde in PBS, and rinsed
and stored at 4 C until FACS analysis.
In a parallel experiment, Jurkat cells
were incubated with supernatants for
48 hours, and photomicrographs were
taken. Cell-size analysis was performed
using a BD Accuri C6 (BD Biosciences,
San Jose, CA) and FlowJo version
10.5.3. (Treestar Inc, Ashland, OR). The
cell size was determined by setting a
gate to exclude the normal-sized cells
of the control sample and only quanti-
fying the cells that were in this “large”
gate, specifically cells that had
increased forward scatter or side scatter
(Hadji et al., 2014).
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Supplementary Figure S1. Syncytin-1 receptors ASCT-1 and ASCT-2 (sodium-dependent neutral amino acid transporter types 1 and 2) are expressed in CTCL,
BeWo chorion carcinoma, and T cells. (a) Expression of ASCT-1 and ASCT-2 in Mac-1 (lymphomatoid papulosis), Mac-2A (primary cutaneous anaplastic
large cell lymphoma), MyLa (mycosis fungoides), BeWo (chorion carcinoma) cell lines and in normal, enriched T cells as detected by immunocytochemistry
with antieASCT-1 and antieASCT-2 antibodies (dark brown). Bar ¼ 20 mm. (b) Western blot analysis of ASCT-1 and ASCT-2 expressed by the CTCL and BeWo
cell lines described above. The 90 kDa and 70 kDa bands in the upper panel represent ASCT-1 proteins of differing glycosylation; the molecular weight of
ASCT-1 is 56 kDa. In the lower panel, ASCT-2 molecular weights vary between 60 kDa and 250 kDa and represent forms with differing glycosylation. CTCL,
cutaneous T-cell lymphoma.
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Supplementary Figure S2. Size distribution of EVs (%). Nanoparticle tracking analysis of CTLC and
BeWo cell line-derived EVs shows a size range of 101 to 250 nm to be the most abundant. The large 751
to 1,000 nm vesicles are absent from BeWo cell line-derived EVs. CTCL, cutaneous T-cell lymphoma; Ev,
extracellular vesicle.
10M
8.0M
3.0
2.5
2.0
1.5
1.0
0.5
0.0
gp60 env
6.0M
SS
C
%
 o
f l
ar
ge
 c
el
ls
4.0M
2.0M
0
0 5.0M 10M
FSC
a
gp60 envb
Jurkat15M 20M
Supplementary Figure S3. Transfected and secreted fusogenic syncytin-1 increases cell size and induces fusions. (a) Size distribution of Jurkat T-cell leukemia
cells treated with media from HEK293T cells transfected with either gp60 (blue trace) or env (red trace). Media from env-transfected HEK293T cells mediate the
cell size increase of Jurkat cells as determined by flow cytometry. FSC represents granulocity, and SSC represents cell size. (b) Photomicrographs of Jurkat cells
treated with media containing gp60 (left) and env (middle and right). Red arrows indicate plasma membrane-enveloped giant fusion cells. Bar ¼ 40 mm. env,
fusogenic particles; FSC, forward scatter; gp60, nonfusogenic particles; SSC, side scatter.
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